FK614 - 10mM in DMSO , Peroxisome proliferator-activated receptor gamma modulator, CAS No.193012-35-0, Peroxisome proliferator-activated receptor gamma modulator

CAS: 193012-35-0 Cat. No.: F656584 Summenformel: C₂₁H₂₃Cl₂N₃O₃S Molekulargewicht: 468.40 PubChem CID: 9869229

GRADE & PURITY 10mM in DMSO

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Übersicht

FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes

In Vitro

FK614 (0.1~10000 nM; 24 hours; CV-1 cells) activates PPARγ-dependent transcription in a concentration-dependent manner. FK614 (0~0.1 μM; 5 days; 3T3-L1 adipocytes) makes triglyceride content increased in a concentration-dependent manner. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 is an insulin sensitizer potentially for treatment of postherpetic neuralgia. FK614 is a non-TZD insulin sensitizer. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

FK614 (0.32~3.2 mg/kg; p.o.; 14 days) dose-dependently reduces plasma glucose level. FK614 (0.1~10 mg/kg; p.o.; 14 days) improves the impaired glucose tolerance. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: db/db Mice Dosage: 0.1~10 mg/kg Administration: P.o. Result: Improved the impaired glucose tolerance. Animal Model: db/db Mice Dosage: 0.32~3.2 mg/kg Administration: P.o. Result: Dose-dependently reduced plasma glucose level.

IC50& Target:PPAR-γ

Specifications

Spezifikationen & Reinheit

10mM in DMSO

Biochemische und physiologische Mechanismen

FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adi

Storage

Store at -80°C

Verschickt in

Dry ice packs + Cold packs

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Aktionsart

MODULATOR

Mechanismus der Wirkung

Peroxisome proliferator-activated receptor gamma modulator

Produkteigenschaften

• ALogP: 5.3

Namen und Kennungen

• Isomere SMILES: CCCCCS(=O)(=O)NC(=O)C1=CC2=C(C=C1)N=C(N2CC3=C(C=C(C=C3)Cl)Cl)C
• Alternative CAS-Nummer: 193012-35-0
• PubChem CID: 9869229
• MeSH-Eintrag: 3-(2,4-dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3 H-benzimidazole-5-carboxamide;FK614 cpd
• Molekulargewicht: 468.40